Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA) — ZEPHYR

Methicillin Resistant Staphylococcus Aureus (MRSA) Clinical Trial

Official title:
Linezolid In The Treatment Of Subjects With Nosocomial Pneumonia Proven To Be Due To Methicillin-Resistant Staphylococcus Aureus

Status Completed

Clinical Trial Summary

To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Methicillin Resistant Staphylococcus Aureus (MRSA)
Pneumonia
Staphylococcal Infections

Clinical Trial Details

NCT number	NCT00084266
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 4
Start date	October 2004
Completion date	March 2010

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00087490` - Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)	Phase 4
	Active, not recruiting	`NCT03343119` - Epidemiology of Resistant Microbial Strains Among Different Groups of People (Healthy, Infected and Exposed to Animals)